PLCG2 and Alzheimer disease: Conversely, allosteric modulators that stabilize active forms of the PLC-γ isozymes might bolster immunotherapies (Guittard et al., 2018) or provide promising leads for the treatment of Alzheimer’s disease where a naturally occurring hypermorphic variant of PLC-γ2 is linked to protection from this disease (Magno et al., 2019).